During the past 12 months, Intercept Pharmaceuticals's average Total Assets Growth Rate was 2.80% per year.
During the past 3 years, the average Total Assets Growth Rate was -12.70% per year.
During the past 5 years, the average Total Assets Growth Rate was 3.30% per year.
During the past 10 years, the average Total Assets Growth Rate was 42.50% per year.
During the past 13 years, Intercept Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 144.00%. The lowest was -12.70%. And the median was 38.10%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercept Pharmaceuticals Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Intercept Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intercept Pharmaceuticals (NAS:ICPT) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Sep. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Intercept Pharmaceuticals's Asset Turnover for the quarter that ended in Sep. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Intercept Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (Intercept Pharmaceuticals) Business Description
Intercept Pharmaceuticals Inc is a biotech company focused on developing and commercializing novel therapeutics to treat progressive non-viral liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICPT has been successfully added to your 